The Effect Metacognitive Therapy on patient with Multiple Sclerosis

INTERVENTION: Behavior Intervention 1: The experimental group received metacognitive therapy for eight weeks. Intervention 2: the control group spent the routine process of the sessions held by the MS Society. the control group spent the routine process of the sessions held by the MS Society. The experimental group received metacognitive therapy for eight weeks Treatment ‐ Drugs CONDITION: Demyelinating diseases of the central nervous system G35‐G37 Multiple SCLEROSIS. ; Demyelinating diseases of the central nervous system PRIMARY OUTCOME: Defense Mechanisms. Timepoint: pre test, Post test, two‐step follow‐up. Method of measurement: Defense Styles Questionnaire (DSQ). Metacognitive Components. Timepoint: pre test, Post test, two‐step follow‐up. Method of measurement: Metacognition Questionnaire ‐30 (MCQ‐30). Resiliency. Timepoint: pre test, Post test, two‐step follow‐up. Method of measurement: Connor and Davidson Resilience Scale (CD‐RISC). Self‐Efficacy. Timepoint: pre test, Post test, two‐step follow‐up. Method of measurement: General Self‐Efficacy Questionnaire. INCLUSION CRITERIA: Main inclusion and exclusion criteria: INCLUSION CRITERIA: The final diagnosis of developing MS by the neurologist, signing a written consent form to participate in the study, having at least a diploma and achieving scores 1 to 4 in EDSS diagnosed by the neurologist. Exclusion criteria: Receiving psychological treatments at least six month prior to entering the study, a history of metabolic diseases like thyroid and absence of more than two sessions.